Potential role of druggable gene SLC15A2 in keratinocyte hyperproliferation in psoriasis.

Authors

Chushan Huang, Pengsheng Chen, Xiaosong Chen

Published in

Gene. Pages 150459. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

Psoriasis is a chronic inflammatory skin disorder marked by abnormal keratinocyte proliferation and persistent immune activation. Identifying genetically supported druggable genes may offer new avenues for therapeutic development. We performed Mendelian randomization and colocalization analyses to identify druggable genes associated with psoriasis. These findings were then validated using an imiquimod-induced psoriasis-like mouse model, single-cell transcriptomics, and in vitro functional assays. SLC15A2 was identified as a gene potentially associated with psoriasis and was upregulated in psoriatic lesions. Single-cell analysis revealed that SLC15A2 was preferentially enriched in hyperproliferative keratinocyte subsets and correlated with cell-cycle activation and proliferation-related signaling pathways. Virtual knockout of SLC15A2 inhibited DNA replication and mitosis-related programs. In M5-stimulated HaCaT cells, knockdown of SLC15A2 decreased intracellular ROS levels and reduced keratinocyte proliferation and migration. Drug screening and molecular docking further indicated that SLC15A2 could be modulated by small molecules. Overall, these results suggest that SLC15A2 is a potential pathogenic gene with therapeutic relevance in psoriasis, providing insights into its role in keratinocyte hyperproliferation.

PMID:
42896660
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.